Insulin-like growth factor-1 - a marker of inflammation in the colon and pancreas in ulcerative colitis

Aim. To determine the correlation of the level of insulin-like growth factor-1 (IGF-1) with the extent of the lesion, the degree of activity of ulcerative colitis (UC), the presence of pseudopolyps and neoplasia of the colon, as well as chronic pancreatitis. Materials and methods. 25 patients with UC aged 30-40 years were examined. All patients underwent endoscopic examination of the colon, endosonographic examination of the pancreas to verify the presence of criteria for chronic pancreatitis (CP) and a blood test for enzyme immunoassay for IGF-1 levels. A correlation analysis was performed with the calculation of Spearman’s rank correlation coefficient (CC) with the determination of the closeness of the relationship between the signs on the Chaddock scale. Results. The study of the dependence of the amount of IGF-1 in the blood serum and the severity of inflammation in the colon showed a high degree of closeness, the CC was equal to -0.871. A significant correlation was also found with the presence of CP in UC (CC -0.601). The determination of the dependence of the presence of pseudopolyps and neoplasia of the colon and the level of IGF-1 did not show a statistically significant correlation between the studied signs. Conclusion. IGF-1 levels have an inverse correlation with the severity of inflammation in the colon and the presence of chronic pancreatitis in UC, which makes it possible to use the amount of this protein as a marker for verifying the degree of UC activity and the presence of CP.

ulcerative colitis, degree of inflammatory activity, chronic pancreatitis, insulin-like growth factor-1

1. Chronic pancreatitis. Clinical guidelines. Moskva; 2024. 115 p. (In Russ.)@@ Хронический панкреатит. Клинические рекомендации. Москва; 2024. 115 с.

2. Fagerhol M.K., Dale I., Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bulletin Européen de Physiopathologie Respiratoire. 1980;16:273-82. doi: 10.1016/b978-0-08-027379-2.50028-4.

3. Yoon J.Y., Park S.J., Hong S.P. et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014;59(4):829-37. doi: 10.1007/s10620-013-2907-3.

4. Osipenko M.F., Livzan M.A., Skalinskaya M.I., Lyalyukova E.A. Concentration of fecal calprotectin in the differential diagnosis of bowel diseases. Terapevticheskii Arkhiv. 2015;87(2):30-3. (In Russ.) doi: 10.17116/terarkh201587230-33.@@ Осипенко МФ, Ливзан МА, Скалинская МИ, Лялюкова ЕА. Концентрация фекального кальпротектина в дифференциальной диагностике заболеваний кишечника. Терапевтический архив. 2015;87(2):30-3. doi: 10.17116/terarkh201587230-33.

5. Nielsen H.L., Engberg J., Ejlertsen T. et al. Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis. Scand J Gastroenterol. 2013;48(5):633-5. doi: 10.3109/00365521.2013.775329.

6. Sherwood R.A. Fecal markers of gastrointestinal inflammation. J Clin Pathol. 2012;65(11):981-5. doi: 10.1136/jclinpath-2012-200901.

7. Tursi A. Biomarkers in diverticular disease of the colon. Dig Dis. 2012;30(1):12-8. doi: 10.1159/000335695.

8. Manz M., Burri E., Rothen C. et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012;12:5. doi: 10.1186/1471-230X-12-5.

9. Daughady W.H., Rotwein P. Insulin-like growth factors I and II, peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev. 1989;10:68-91. doi: 10.1210/edrv-10-1-68.

10. Filus A., Zdrojewicz Z. Insulin-like growth factor 1 (IGF-1) - structure and the role in the human body. Pediatr Endocrinol Diabetes Metab. 2014;22:161-9. doi: 10.18544/PEDM-20.04.0016.

11. Genre F., López Mejías R., Rueda Gotor J. et al. IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF alpha therapy. Biomed Res Int. 2014;2014:671061. doi: 10.1155/2014/671061.

12. Bancu I., Navarro Díaz M., Serra A. et al. Low Insulin-like growth factor 1 level in obesity nephropathy: a new risk factor? PLoS One. 2016;11: e0154451. doi: 10.1371/journal.pone.0154451.

13. Daughady W.H., Hall K., Salmon J.W.D. et al. On the nomenclature of the somatomedins and insulin-like growth factors. Endocrinology. 1987;121:1911-2. doi: 10.1210/endo-121-5-1911.

14. Gilbert S., Zhang R., Denson L. et al. Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. EMBO Mol Med. 2012;4:109-24. doi: 10.1002/emmm.201100192.

15. Han X., Sosnowska D., Bonkowski E.L. et al. Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology. 2005;129:185-203. doi: 10.1053/j.gastro.2005.05.018.

16. Eivindson M., Grønbaek H., Flyvbjerg A. et al. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21(9):1063-71. doi: 10.1111/j.1365-2036.2005.02449.x.

17. Eivindson M., Grønbaek H., Flyvbjerg A. et al. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease.Int. J. Mol. Sci. 2017;18:2046. doi: 10.3390/ijms18102046.

18. Katsanos K.H., Tsatsoulis A., Christodoulou D. et al. Reduced serum insulin-like growth factor-1 and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res. 2001;11(6):364-7. doi: 10.1054/ghir.2001.0248.

19. Han X., Ren X., Jurickova I. et al. Regulation of intestinal barrier function by signal transducer and activator of transcription 5b. Gut. 2009;58:49-58. doi: 10.1136/gut.2007.145094.

20. Okhlobystin A.V., Kucheryavyy Yu.A. Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of chronic pancreatitis (Draft). Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2013;23(1):66-87. (In Russ.)@@ Охлобыстин АВ, Кучерявый ЮА. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению хронического панкреатита (Проект). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013;23(1):66-87.

21. Bach L.A. Endothelial cells and the IGF system. J Mol Endocrinol. 2015;54: R1-R13. doi: 10.1530/JME-14-0215.

22. Ansarullah Jain C., Far F.F. et al. Inceptor counteracts insulin signaling in β-cells to control glycaemia. Nature. 2021;590(7845):326-31. doi: 10.1038/s41586-021-03225-8.

23. Fukui T., Fukase A., Sasamori H. et al. Association between insulin-like growth factor 1 and pancreatic volume in type 1 and type 2 diabetes: cross-sectional study of a Japanese population. Growth Horm IGF Res. 2021;59:101396. doi: 10.1016/j.ghir.2021.101396.